RESUMO
The toxicity, immunogenic properties and protective activity of the live culture of E. coli M17 and antigenic preparations obtained from cell suspensions of this strain have been studied under experimental conditions. As revealed in experiments on mice, E. coli M17 live culture has low virulence, moderate toxicity and provides the protection of immunized mice from challenge with homologous and highly virulent E. coli strains. E. coli M17 live culture, when introduced orally or intravenously into rabbits, ensures the synthesis of 02 and H6 antibodies. Blood sera taken from immunized rabbits yield better results than initial sera in experiments on the passive protection of mice. The results of our experiments show the expediency of the clinical trials of Colibacterin as a perspective Escherichia live oral vaccine.
Assuntos
Vacinas Bacterianas/imunologia , Colicinas/imunologia , Escherichia coli/imunologia , Animais , Antígenos de Bactérias/imunologia , Antígenos de Bactérias/toxicidade , Vacinas Bacterianas/toxicidade , Colicinas/toxicidade , Relação Dose-Resposta Imunológica , Avaliação Pré-Clínica de Medicamentos , Escherichia coli/patogenicidade , Infecções por Escherichia coli/prevenção & controle , Imunização , Camundongos , Coelhos , Fatores de Tempo , Vacinas Atenuadas/imunologia , Vacinas Atenuadas/toxicidade , Virulência/imunologiaRESUMO
In experiments of the passive protection of mice the protective properties of sera obtained from humans before and after their immunization with Proteus vaccine used as a monopreparation or in combination with staphylococcal toxoid and/or pyoimmunogen were studied. When introduced in a single subcutaneous injection, Proteus vaccine prepared from soluble antigenic complexes ensured an increase in the protective properties of sera. The second injection of the vaccine essentially enhanced the protective potency of the sera of the immunized donors. The therapeutic injection of Proteus vaccine ensured the essential increase of the protective properties of the sera. This increase could be experimentally detected within at least 25-30 days from the beginning of immunization. The immunization of volunteers with Proteus vaccine in combination with pyoimmunogen and adsorbed staphylococcal toxoid ensured the maximum increase of the protective properties of their sera.
Assuntos
Antígenos de Bactérias/imunologia , Vacinas Bacterianas/imunologia , Soros Imunes/imunologia , Proteus vulgaris/imunologia , Vacinação , Animais , Relação Dose-Resposta Imunológica , Avaliação Pré-Clínica de Medicamentos , Feminino , Humanos , Soros Imunes/isolamento & purificação , Imunização Passiva , Masculino , Camundongos , Infecções por Proteus/prevenção & controle , Vacinas contra Pseudomonas , Pseudomonas aeruginosa/imunologia , Solubilidade , Toxoide Estafilocócico/imunologia , Fatores de Tempo , Vacinas CombinadasRESUMO
NFR/NM, NFS/NM inbred mice and M : CFLP random bred mice have been shown to possess immunobiological properties making them suitable for the evaluation of the quality of pertussis vaccines and for their standardization. NFS/NM mice are highly sensitive to the histamine-sensitizing factor, while M : CFLP mice are sensitive to the lienotoxic factor of pertussis vaccines. All these substrains of mice have sufficient fertility for their breeding under the conditions of a commercial breeding establishment.
Assuntos
Camundongos Endogâmicos/fisiologia , Animais , Animais de Laboratório , Avaliação Pré-Clínica de Medicamentos , Estudos de Avaliação como Assunto , Feminino , Dose Letal Mediana , Masculino , Camundongos , Vacina contra Coqueluche/imunologia , Controle de Qualidade , ReproduçãoRESUMO
A vaccine prepared from Proteus soluble antigens obtained by the disintegration of microbial cells with hydroxylamine is proposed. In animal experiments the vaccine has proved to be nontoxic when injected in large single doses or in smaller doses over a prolonged period and capable of protecting mice and rabbits from Proteus infection. No pronounced postvaccinal complications have been registered in humans immunized with the vaccine. The possibility of using the vaccine for immunizing donors with the aim of obtaining hyperimmune anti-Proteus plasma and for the active vaccinal therapy of patients with Proteus infection has been shown.